Request an Appointment

To request an appointment with our clinical team or for more information on our solutions and services, please complete the form provided or call our office at 786.780.1188. Rezilir is open for all in-person visits, however as the COVID-19 pandemic continues, we are offering all current and future patients the option of Telemedicine. Our dedicated Rezilir Health® staff will contact you as soon as possible. We look forward to welcoming you to our Rezilir family where Hope Is Happening.

  • This field is for validation purposes and should be left unchanged.

Comparison of Leqembi to Precision Medicine

Jul 21st 2023 | By Rezilir Health LLC.

Change in Cognitive Score using Lecanenab

On July 5th 2023, the FDA gave full approval for Leqembi, which is a monoclonal antibody for patients with amyloid and mild cognitive impairment.

Here is a brief summary on how the drug stacks against the Precision Medicine Approach we are using; We are happy to discuss this issue further with anyone in our community.

Lecanemab Research Grid
Lecanemab Research Grid
Lecanemab Research Grid
Lecanemab Research Grid

Van Dyck et al. Lecanemab in early Alzheimer’s Disease N Engl J Med 2023; 388:9-21 DOI: 10.1056/NEJMoa2212948

Toups et al. Precision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project. Journal of Alzheimer’s Disease 88 (2022) 1411-1421.

Recent Blog Posts